Bank Of Montreal

Direxion Daily Semicondct Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

VS TR -1x Short VIX Futures ETF

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

Direxion Daily Financial Bull 3X ETF

ProShares UltraPro Dow30

United States Natural Gas

ARK Innovation ETF

VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Semicondct Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Financial Bear 3X Shar

Direxion Daily Small Cap Bear 3X ETF

United States Oil Fund

Direxion Technology Bear 3X Shares

MicroSectors Gold Miners 3X Leveraged ETN

Granite Point Mortgage Trust Inc. Common Stock

Genworth Financial Inc Common Stock

RE/MAX Holdings Inc. Class A Common Stock

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

TKO Group Holdings Inc. Class A Common Stock

WESCO International Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Affiliated Managers Group Inc. Common Stock

Reddit Inc. Class A Common Stock

Carvana Co. Class A Common Stock

Hecla Mining Company Common Stock

Halliburton Company Common Stock

CVR Energy Inc. Common Stock

UBS Group AG Registered Ordinary Shares

Spotify Technology S.A. Ordinary Shares

Telefonica SA Common Stock

Allstate Corporation (The) Common Stock

ServiceNow Inc. Common Stock

ConocoPhillips Common Stock

Cleveland-Cliffs Inc. Common Stock

Click here to get full coverage on (RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

(RYTM) Technical Pivots with Risk Controls  news.stocktradersdaily.com

(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism  MSN

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN

Click here to get full coverage on Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...  Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update  GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan

Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit  Stock Titan

Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan

Click here to get full coverage on RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Zacks Investment Research

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study  Zacks Investment Research

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Zacks Investment Research

Click here to get full coverage on When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Breakeven? - simplywall.st

When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Breakeven?  simplywall.st

When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Breakeven? - simplywall.st

Click here to get full coverage on $RYTM stock is up 7% today. Here's what we see in our data. - Nasdaq

$RYTM stock is up 7% today. Here's what we see in our data.  Nasdaq

$RYTM stock is up 7% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ)  Seeking Alpha

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Click here to get full coverage on Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway  MedCity News

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Nasdaq

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know  Nasdaq

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter  GlobeNewswire

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire

Click here to get full coverage on (RYTM) On The My Stocks Page - news.stocktradersdaily.com

(RYTM) On The My Stocks Page  news.stocktradersdaily.com

(RYTM) On The My Stocks Page - news.stocktradersdaily.com

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?  Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates  Nasdaq

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE®  GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire

Click here to get full coverage on Insider Sale: EVP of $RYTM Sells 55,803 Shares - Nasdaq

Insider Sale: EVP of $RYTM Sells 55,803 Shares  Nasdaq

Insider Sale: EVP of $RYTM Sells 55,803 Shares - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus

Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal  GuruFocus

Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus

Click here to get full coverage on We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth - Yahoo Finance

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth  Yahoo Finance

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth - Yahoo Finance

Click here to get full coverage on RHYTHM PHARMACEUTICLS Earnings Results: $RYTM Reports Quarterly Earnings - Nasdaq

RHYTHM PHARMACEUTICLS Earnings Results: $RYTM Reports Quarterly Earnings  Nasdaq

RHYTHM PHARMACEUTICLS Earnings Results: $RYTM Reports Quarterly Earnings - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News  GuruFocus

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus

Click here to get full coverage on Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication - BioSpace

Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication  BioSpace

Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication - BioSpace

Click here to get full coverage on RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report  TradingView

RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Click here to get full coverage on Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration  GlobeNewswire

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire

Click here to get full coverage on Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo Finance

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder  Yahoo Finance

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire

Rhythm Pharmaceuticals Announces Orphan Drug Designation  GlobeNewswire

Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire

Click here to get full coverage on Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity  GlobeNewswire

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire

Click here to get full coverage on Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line  Yahoo Finance

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM) - Seeking Alpha

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM)  Seeking Alpha

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM) - Seeking Alpha

Click here to get full coverage on Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update  GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology - GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology  GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology - GlobeNewswire

Click here to get full coverage on 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know  Benzinga

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga

Click here to get full coverage on Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...  Yahoo

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo

Click here to get full coverage on Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks

Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results  TipRanks

Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus

Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound  GuruFocus

Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus

Click here to get full coverage on Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com

Canaccord raises Rhythm Pharma stock target to $92, maintains buy  Investing.com

Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com

Click here to get full coverage on Apple introduces the 2025 Black Unity Collection - Apple

Apple introduces the 2025 Black Unity Collection  Apple

Apple introduces the 2025 Black Unity Collection - Apple

Click here to get full coverage on FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter

FDA nod for Rhythm Pharma’s Imcivree  The Pharma Letter

FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter

Click here to get full coverage on Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com

Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08  marketscreener.com

Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com

Click here to get full coverage on Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq

Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide  Nasdaq

Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq

Click here to get full coverage on BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63  Investing.com

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com

Click here to get full coverage on Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Yahoo Finance

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences  Yahoo Finance

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News

Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo?  Daily Chhattisgarh News

Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News

Click here to get full coverage on Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView

Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug  TradingView

Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView

Click here to get full coverage on Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com

Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates  Investing.com

Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com

Click here to get full coverage on Rhythm Pharmaceuticals corporate controller sells shares for $18,655 - Investing.com

Rhythm Pharmaceuticals corporate controller sells shares for $18,655  Investing.com

Rhythm Pharmaceuticals corporate controller sells shares for $18,655 - Investing.com

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript - Insider Monkey

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript  Insider Monkey

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Rhythm Pharma's drug for rare obesity meets late-stage trial goal - TradingView

Rhythm Pharma's drug for rare obesity meets late-stage trial goal  TradingView

Rhythm Pharma's drug for rare obesity meets late-stage trial goal - TradingView

Click here to get full coverage on Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com Nigeria

Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com  Investing.com Nigeria

Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com Nigeria

Click here to get full coverage on Rhythm Pharmaceuticals shares rise on raised target to $80 - Investing.com

Rhythm Pharmaceuticals shares rise on raised target to $80  Investing.com

Rhythm Pharmaceuticals shares rise on raised target to $80 - Investing.com

Click here to get full coverage on Rhythm Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Rhythm Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating  Investor's Business Daily

Rhythm Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Click here to get full coverage on Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia

Rhythm Pharma stock soars to all-time high of $69.7  Investing.com Australia

Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia

Click here to get full coverage on Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com South Africa

Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com  Investing.com South Africa

Rhythm Pharmaceuticals Inc (RYTM)

Price Chart

Key Statistics

Technicals

About RYTM

Latest News

(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers